Screening Limits for Therapeutic Substances

For the purpose of AR 257, it is hereby notified that screening limits applicable to the following therapeutic substances, as approved by Racing Australia, are set out as follows (new items in red):

- acepromazine – 0.02 nanograms per millilitre (ng/mL) in plasma
- acepromazine – 10ng/mL of the 2-(1-hydroxyethyl) promazine sulphoxide metabolite in urine
- betamethasone - 0.20ng/mL in urine
- butorphanol – 0.01ng/mL in plasma
- butorphanol – 1ng/mL in urine
- carprofen – 100ng/mL in plasma
- carprofen – 100ng/mL in urine
- clenbuterol – 0.1ng/mL in urine
- dantrolene – 3ng/mL of the 5-hydroxydantrolene metabolite in unhydrolysed urine
- dantrolene - 0.1 ng/mL of the 5-hydroxydantrolene metabolite in plasma (Date of Effect 1 May 2025)
- detomidine – 0.02ng/mL of the 3'-hydroxydetomidine metabolite in plasma
- detomidine – 2ng/mL of the 3'-hydroxydetomidine metabolite in urine
- dexamethasone – 0.2ng/mL in plasma (Date of Effect: 1 February 2024)
- dexamethasone – 0.2ng/mL in urine
- diclofenac – 50ng/mL in urine
- dipyrone – 1000ng/mL of the 4-methylaminoantipyrine metabolite in urine
- eltenac – 50ng/mL in urine
- firocoxib – 2ng/mL in plasma
- flunixin – 1ng/mL in plasma
- flunixin – 100ng/mL in urine
- frusemide – 0.1ng/mL in plasma
- frusemide – 50ng/mL in urine
- hyoscine butylbromide (or n-butylscopolammonium) – 0.05ng/mL in plasma
- hyoscine butylbromide (or n-butylscopolammonium) – 25ng/mL in urine
- ipratropium - 0.25ng/mL in urine
- ketoprofen – 2ng/mL in plasma under the condition of a single IV or oral dose
- ketoprofen - 100ng/mL in urine
- lignocaine – 0.05ng/mL in plasma
- lignocaine – 10ng/mL of the 3'-hydroxylignocaine metabolite in urine
- meclofenamic acid – 5ng/mL in plasma
- meclofenamic acid – 250ng/mL in urine
- medetomidine – 0.02ng/mL of 3'-hydroxymedetomidine in plasma
- medetomidine – 5ng/mL of 3'-hydroxymedetomidine in urine
- meloxicam – 1ng/mL in plasma
- meloxicam – 10ng/mL in urine

- mepivacaine – 0.05ng/mL in plasma
- mepivacaine – 10ng/mL of the 3’-hydroxymepivacaine metabolite in urine
- methocarbamol – 100ng/mL in urine (when restricted to a single oral or IV treatment of no more than 5 grams of methocarbamol)
- naproxen – 250ng/mL in urine
- procaine – 0.02ng/mL in plasma (Date of Effect: 1 February 2024)
- procaine – 20 ng/mL in urine (Date of Effect: 1 February 2024)
- phenylbutazone – 100ng/mL in plasma
- phenylbutazone – 100ng/mL in urine
- romifidine – 1ng/mL in urine
- salbutamol – 0.5ng/mL in urine
- triamcinolone acetonide – 0.5ng/mL in urine
- vedaprofen – 5ng/mL in plasma
- vedaprofen – 50ng/mL in urine”
- xylazine – 0.05 ng/mL in plasma (Date of Effect 1 May 2025)
- xylazine – 10 ng/mL of the 4'-hydroxyxylazine metabolite in urine (Date of Effect 1 May 2025)

1 May 2025